Stocks
Intraday Booster
Sector Booster
Stock Screener
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersStock Screener
Create Screener
Explore Screeners
Community Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNew
EMA Screener
SMA Screener
WMA Screener
OHLC Screener
Fibonacci Screener
VWAP Screener
Pivot Point Screener
Overlay Screener
Trend Indicator Screener
Volume Based Indicator Screener
Overbought/Sold Screener
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMore
Global Market Today
Global Indices
Indian Indices
NIfty Today
Gold Price TodayNew
Silver Price TodayNew
Platinum Price TodayNew
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataSector Booster
FnO Movements
NSE F&O Lot Size
Ban List
Technical Dashboard
Sector AnalysisNew
Result Calendar
IPO Calendar
Economic Calendar
Nippon India NIFTY Pharma ETF Growth Plan
Nippon India NIFTY Pharma ETF Growth Plan valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Nippon India NIFTY Pharma ETF Growth Plan, framed against the sector median so the premium or discount is obvious at a glance.
Valuation
Profitability
Growth
Financial Health
Nippon India NIFTY Pharma ETF Growth Plan financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Nippon India NIFTY Pharma ETF Growth Plan, switchable between annual and quarterly views, consolidated or standalone.
Nippon India NIFTY Pharma ETF Growth Plan segment analysis: revenue and profit mix.
Disclosed business segments at Nippon India NIFTY Pharma ETF Growth Plan with their share of revenue and profit, switchable between consolidated and standalone reporting.
Nippon India NIFTY Pharma ETF Growth Plan discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Nippon India NIFTY Pharma ETF Growth Plan investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Nippon India NIFTY Pharma ETF Growth Plan, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Nippon India NIFTY Pharma ETF Growth Plan's investment case rests on 8 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Diversified exposure to Nifty Pharma sector offers strategic investment.
High daily trading volumes ensure strong liquidity for investors.
Current price near 52-week high suggests positive market sentiment.
Positive 5-day return of 0.56% indicates short-term momentum.
Moderate 26-week return of 6.20% shows steady performance.
What can break it.
Absence of traditional metrics hinders fundamental company analysis.
Zero dividend yield may not attract income-focused investors.
Notable 52-week price fluctuations indicate potential volatility concerns.
Year-to-date return of -2.39% shows recent underperformance.
Drug pricing pressures pose a significant risk to underlying pharma companies.
What would change my mind.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Nippon India NIFTY Pharma ETF Growth Plan peer comparison — same-sector benchmarks.
No comparable peer set was disclosed for Nippon India NIFTY Pharma ETF Growth Plan.
Peer comparison data is not available.
Nippon India NIFTY Pharma ETF Growth Plan technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Nippon India NIFTY Pharma ETF Growth Plan — derived from the live tape, not yesterday's close.
Nippon India NIFTY Pharma ETF Growth Plan last traded at ₹24.9 with an intraday range of ₹24.09–₹25.08 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹24.90| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 27.27 | +2.37 | +9.52% |
| R3 | 26.28 | +1.38 | +5.54% |
| R2 | 25.68 | +0.78 | +3.13% |
| R1 | 25.29 | +0.39 | +1.57% |
| PIVOT | 24.69 | -0.21 | -0.84% |
| CURRENT | 24.90 | — | — |
| S1 | 22.32 | -2.58 | -10.36% |
| S2 | 23.31 | -1.59 | -6.39% |
| S3 | 23.70 | -1.20 | -4.82% |
| S4 | 24.30 | -0.60 | -2.41% |
PHARMABEES is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 24.09 ~ 25.08
Trading Inside opening range
Nippon India NIFTY Pharma ETF Growth Plan delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Nippon India NIFTY Pharma ETF Growth Plan over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Nippon India NIFTY Pharma ETF Growth Plan stood at 53.1% of traded volume, against a 20-day average of 63.4%.
Nippon India NIFTY Pharma ETF Growth Plan announcements: results, concalls, ratings, M&A.
Filings Nippon India NIFTY Pharma ETF Growth Plan sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Nippon India NIFTY Pharma ETF Growth Plan dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Nippon India NIFTY Pharma ETF Growth Plan has declared, sequenced by announce and record date.
Nippon India NIFTY Pharma ETF Growth Plan corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Nippon India NIFTY Pharma ETF Growth Plan: business, sector, key facts.
What Nippon India NIFTY Pharma ETF Growth Plan does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Nippon India NIFTY Pharma ETF Growth Plan is a listed Indian equity, listed as NSE: PHARMABEES.
Nippon India NIFTY Pharma ETF Growth Plan
Bio not generated
Questions investors ask about Nippon India NIFTY Pharma ETF Growth Plan (PHARMABEES).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Nippon India NIFTY Pharma ETF Growth Plan (PHARMABEES)?
The current share price of Nippon India NIFTY Pharma ETF Growth Plan (PHARMABEES) is ₹24.9. Today, the stock has gained by ₹0.11 (0.44%), trading in a range of ₹24.09 to ₹25.08. The stock opened at ₹25.08 with a trading volume of 37,86,588 shares.
02Is Nippon India NIFTY Pharma ETF Growth Plan stock a good investment for long-term?
Nippon India NIFTY Pharma ETF Growth Plan can be considered for long-term investment based on several factors. The company has a market capitalization of ₹0 crores, P/E ratio of 0.00, ROE of 0.00%, and ROCE of 0.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Nippon India NIFTY Pharma ETF Growth Plan stock?
The 52-week high price of Nippon India NIFTY Pharma ETF Growth Plan (PHARMABEES) is ₹26.52, while the 52-week low is ₹21.11. Currently trading at ₹24.9, the stock is 70.1% away from its 52-week low and 6.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Nippon India NIFTY Pharma ETF Growth Plan stock at the current price?
Whether to buy Nippon India NIFTY Pharma ETF Growth Plan stock at ₹24.9 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of N/A. Today's performance shows a gain of 0.44%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Nippon India NIFTY Pharma ETF Growth Plan and when is the next dividend?
Nippon India NIFTY Pharma ETF Growth Plan offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹24.9, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹0.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Nippon India NIFTY Pharma ETF Growth Plan?
Nippon India NIFTY Pharma ETF Growth Plan's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: N/A, ROE: 0.00%, ROCE: 0.00%, Dividend Yield: 0.00%, EPS: ₹0.00, Book Value: ₹0, Debt-to-Equity: 0.00, and Current Ratio: N/A. The company's market cap stands at ₹0 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Nippon India NIFTY Pharma ETF Growth Plan stock performing today in the market?
Nippon India NIFTY Pharma ETF Growth Plan stock opened at ₹25.08 and is currently trading at ₹24.9, showing a gain of ₹0.11 (0.44%). The intraday high is ₹25.08 and low is ₹24.09. The trading volume stands at 37,86,588 shares, indicating strong market participation today.
08What is the P/E ratio of Nippon India NIFTY Pharma ETF Growth Plan and what does it indicate?
Nippon India NIFTY Pharma ETF Growth Plan has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹0.00, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Nippon India NIFTY Pharma ETF Growth Plan (PHARMABEES) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
Menu